Metabolomics in chronic hepatitis C: Decoding fibrosis grading and underlying pathways

Area of Science:

• Hepatology
• Metabolomics
• Biomarker Discovery

Background:

• Chronic Hepatitis C (CHC) affects millions globally, causing significant liver damage.
• Accurate staging of liver fibrosis is critical for CHC patient management and prognosis.
• Current fibrosis assessment methods like histology and imaging have limitations.

Purpose of the Study:

• To discover novel molecular biomarkers for stratifying CHC-related liver lesions.
• To elucidate the molecular mechanisms underlying CHC fibrosis progression.
• To identify potential prognostic biomarkers for CHC patients.

Main Methods:

• Plasma samples from 46 CHC patients across fibrosis grades (F1-F4) and 50 healthy controls were analyzed.
• Untargeted metabolomic profiling using mass spectrometry identified plasma metabolites.
• Statistical analysis was employed to detect differential metabolites between fibrosis groups.

Main Results:

• A distinct profile of six differential metabolites was identified for each fibrosis grade.
• This six-metabolite signature demonstrated effective clustering of patients by fibrosis stage.
• The metabolite profile showed high efficiency in discriminating between different grades of liver fibrosis.

Conclusions:

• The identified metabolite profile shows potential as a prognostic biomarker for CHC fibrosis.
• Liquid biopsy analysis of plasma metabolites is a viable strategy for discovering biomarkers.
• This approach can effectively stratify CHC patients based on their liver fibrosis stage.